Clinical trials: FSGS
Focal Segmental Glomerulosclerosis
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental…
- Trial name
- FONTII (NCT00814255)
- Testing
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Where
- 18 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
Childhood Idiopathic Nephrotic Syndrome
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
Background Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine).
- Trial name
- NEPHRUTIX (NCT01268033)
- Testing
- Rituximab
- Where
- 24 sites in Belgium, France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Limoges
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nephrotic Syndrome
Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)
Background. Patients, especially children, with steroid-dependent or multirelapsing nephrotic syndrome (NS) secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS) on continuous…
- Trial name
- NEMO (NCT00981838)
- Testing
- Rituximab
- Where
- 7 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Mario Negri Institute for Pharmacological Research